Use of a new, low-pH immunoglobulin G preparation during episodes of bacteremia in the rat.

A rapidly expanding role for immunoglobulin G preparations in conditions other than the classical immunodeficiency syndromes is evident. This relatively new concept of treatment with polyclonal antibody has been tested in the rat with severe Salmonella typhimurium bacteremia with use of a newly developed, native immunoglobulin G preparation for intravenous use (IGIV pH 4.25). IGIV pH 4.25 increased survival time and decreased absolute mortality, prevented hypotension and acidosis, and ameliorated or prevented changes in variables indicative of organ damage during S. typhimurium bacteremia in the rat. Intravenous infusion of IGIV pH 4.25 at high rates did not cause further deterioration in the arterial blood pH in the acid-base-compromised rat and hence should not cause clinically significant decreases in pH in patients with compromised acid-base regulating systems.

[1]  M. Klegerman,et al.  Protective levels of human immunoglobulin G antibody to group B streptococcus type Ib , 1984, Infection and immunity.

[2]  M. Collins,et al.  Comparative anti-Pseudomonas aeruginosa activity of chemically modified and native immunoglobulin G (human), and potentiation of antibiotic protection against Pseudomonas aeruginosa and group B Streptococcus in vivo. , 1984, The American journal of medicine.

[3]  A. Mason,et al.  Replacement therapy with modified immunoglobulin G in burn patients: preliminary kinetic studies. , 1984, The American journal of medicine.

[4]  B. Pirofsky.  Intravenous immune globulin therapy in hypogammaglobulinemia. A review. , 1984, The American journal of medicine.

[5]  R. Gale,et al.  Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trial. , 1984, The American journal of medicine.

[6]  H. Hill,et al.  Comparative opsonic activity of intravenous gamma globulin preparations for common bacterial pathogens. , 1984, The American journal of medicine.

[7]  W. Rosse,et al.  Intravenous immunoglobulin administration in the treatment of severe chronic immune thrombocytopenic purpura. , 1984, The American journal of medicine.

[8]  E. Besa.  Use of intravenous immunoglobulin in chronic lymphocytic leukemia. , 1984, The American journal of medicine.

[9]  J. Naglich,et al.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa. Treatment with intravenous immune globulin. , 1984, The American journal of medicine.

[10]  M. Collins,et al.  Anti-Pseudomonas aeruginosa activity of an intravenous human IgG preparation in burned mice. , 1983, The Journal of trauma.

[11]  Samuel R. Wilson,et al.  MODIFIED HUMAN IMMUNE SERUM GLOBULIN FOR INTRAVENOUS ADMINISTRATION: IN VITRO OPSONIC ACTIVITY AND IN VIVO PROTECTION AGAINST GROUP B STREPTOCOCCAL DISEASE IN SUCKLING RATS , 1982, Acta paediatrica Scandinavica.

[12]  J. Lundblad,et al.  A New Preparation of Modified Immune Serum Globulin (Human) Suitable for Intravenous Administration , 1981, Vox sanguinis.

[13]  R. Buckley,et al.  SAFETY AND PATIENT ACCEPTABILITY OF INTRAVENOUS IMMUNE GLOBULIN IN 10% MALTOSE , 1980, The Lancet.

[14]  R. L. Fulton,et al.  Multiple system organ failure. The role of uncontrolled infection. , 1980, Archives of surgery.

[15]  B. Golding,et al.  Intravenous immunoglobulin therapy for antibody deficiency. , 1979, Clinical and experimental immunology.

[16]  I. Chaudry,et al.  Effect of sepsis on tissue adenine nucleotide levels. , 1979, Surgery.

[17]  W. Mcdougal,et al.  Glucose-dependent hepatic membrane transport in nonbacteremic and bacteremic thermally injured patients. , 1977, The Journal of surgical research.

[18]  R. Beart,et al.  Multiple organ failure. , 1977, Surgery, gynecology & obstetrics.

[19]  R. Colman,et al.  Kinin activation in the blood of patients with sepsis. , 1976, Surgery, gynecology & obstetrics.

[20]  B. Buchanan,et al.  Bioassay of endotoxin clearance in vivo and by perfused rat liver. , 1976, The American journal of physiology.

[21]  A. Baue.  Multiple, progressive, or sequential systems failure. A syndrome of the 1970s. , 1975, Archives of surgery.

[22]  S. Davis,et al.  Efficacy of modified human immune serum globulin in the treatment of experimental murine infections with seven immunotypes of Pseudomonas aeruginosa. , 1975, The Journal of infectious diseases.

[23]  R. Lillehei,et al.  THE NATURE OF IRREVERSIBLE SHOCK: EXPERIMENTAL AND CLINICAL OBSERVATIONS. , 1964, Annals of surgery.

[24]  R. Lillehei,et al.  THE NATURE OF EXPERIMENTAL IRREVERSIBLE SHOCK WITH ITS CLINICAL APPLICATION , 1964, International anesthesiology clinics.

[25]  W. R. Scott,et al.  Visceral factors in shock. , 1962, JAMA.

[26]  R. Lillehei,et al.  The Intestinal Factor in Irreversible Endotoxin Shock , 1958, Annals of surgery.

[27]  B. Benacerraf,et al.  Effect of bacterial endotoxins on the reticuloendothelial system. , 1957, Federation proceedings.

[28]  E. Te,et al.  Efficaciousness of immunoglobulin G prophylaxis on mortality and physiological variables in gram-negative peritonitis in rodents. , 1985 .

[29]  H. Bernard,et al.  Reticuloendothelial phagocytic response to bacterial challenge after traumatic shock. , 1977, Circulatory shock.

[30]  Schildt Be.  Function of the RES after thermal and mechanical trauma in mice. , 1970 .